Is MOTS-c Legal in Texas? How to Access It Legally
HealthRX.com
No federal pathway makes MOTS-c clearly legal in Texas
See the public record for MOTS-c
At a glance
- FDA status / Not an approved drug and not a component of one [1]
- Compounding lists / In none of the three categories for state-licensed pharmacies; absent from the outsourcing-facility list [2][6][3]
- Advisory vote / July 23, 2026 vote favored listing; advice only, not binding [7][4]
- Draft HHS policy / Nonbinding; MOTS-c acetate by injection only, if conditions are met [4][5]
- Human data / FDA found no published study giving MOTS-c to a person [1]
- Sport / WADA prohibits it at all times under S4.4.1 [8]
Is MOTS-c approved or on FDA's compounding lists?
No. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [9]. It is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no European or Japanese pharmacopeia listing and no product authorized by the European Medicines Agency [1]. The free base and the acetate salt are treated as different bulk substances [1].
For state-licensed physicians and pharmacies, FDA describes three ways a bulk substance can qualify for compounding: an applicable USP or National Formulary monograph, use as a component of an FDA-approved drug, or inclusion on FDA's bulks list [3]. MOTS-c meets none of those. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is absent from the outsourcing-facility list (updated March 21, 2025), so FDA's category 1 policy does not cover it [2][6][3].
FDA's page on bulk substances that may present significant safety risks (content dated 04/22/2026) places MOTS-c in the nominated-but-withdrawn table. FDA says it has not identified human exposure data on MOTS-c given by any route and lacks important information about its safety. Removal from category 2 was not a finding that it is safe [10].
What would the draft HHS policy do?
HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192) naming MOTS-c among six peptides and covering MOTS-c acetate by subcutaneous or intramuscular injection [4][5]. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it if conditions are met. Those conditions include a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [4][5]. The notice says it does not establish any rights for any person, is not binding on HHS or the public, and may be revisited, for example after a safety signal or product quality issue [4].
FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding MOTS-c to the bulks list, against FDA staff's recommendation. That vote is advice only; MOTS-c is not on the list, and adding it takes formal rulemaking [7][4].
Does the federal position settle Texas access?
No. Texas law is separate, and none of the federal documents says Texas permits prescribing or compounding MOTS-c. Federally, MOTS-c is absent from FDA's compounding lists, and the draft policy describes only conditional, nonbinding enforcement discretion for the acetate injection [2][3][4][5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [4].
FDA found no published study in which MOTS-c was given to a human; human studies measured the body's own MOTS-c, including after exercise [1][11][12]. WADA names MOTS-c in S4.4.1 (AMPK activators) and prohibits it at all times, in and out of competition, on the 2026 and 2027 Lists [8][13].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Is MOTS-c legal in Texas?
Can a Texas pharmacy compound MOTS-c?
Did the July 2026 advisory vote change that?
Is MOTS-c safe?
References
Show all 13 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- World Anti-Doping Agency.